Indeed, glycosphingolipid biosynthesis was shown to regulate drug sensitivity in clinically relevant models of drug-resistant chronic myeloid leukemias, through modulation of both the expression and activity of the drug efflux proteins ABCB1 and ABCC1 [25]. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.